<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca | LYNPARZA">
<title>AstraZeneca | LYNPARZA</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<script src="http://ajax.googleapis.com/ajax/libs/jquery/1.9.1/jquery.min.js"></script>
<style type="text/css">
.bodyContentLeft {margin-top: 236px; margin-left: 68px; width:440px; height:305px;}
.bodyContentRight {width:458px; height:231px; margin-top: -263px; margin-left: 540px;}
.bodyContentRight > li, .bodyContentLeft > li { margin-bottom: 15px;  line-height: 23px;}
h4 {font-size:24px; font-family: "lexiRegular"; margin-bottom: 24px;}

ul { list-style: none; font-family: "HelveticaNeueLTStd"; font-size:18px; color: white; }
.bodyContentRight > li:first-child {margin-left:-15px;}
.bodyContentRight > li:nth-child(2), .bodyContentRight > li:nth-child(3) {list-style: disc;}
.bodyContentRight > li:last-child {font-size:14px; font-family: "HelveticaNeueLTStd";}
</style> 

</head>
<body>
	<section id="container">

    	<article class="content">

            <span></span>
        </article>
    		         <!--popups -->
        <div class="popup">
            <span class="close"></span>
                	<ul class="bodyContentLeft">
                    	<h4>Welte <em>et al.</em> study design:</h4>
                    	<li>A 12-week, randomised, double-blind, parallel-group<br />
                    		study in 660 patients (≥40 yrs) with moderate-severe<br />COPD (FEV<sub>1</sub> ≤50% predicted normal and a history<br />
                    		of exacerbations requiring systemic steroids<br /> and/or antibiotics).
                    	</li>
                    	<li>Patients received tiotrpium (18Ug) once-daily plus either<br />Symbicort<sup>&reg;</sup> 400/12ug or placebo twice daily. Terbutaline
                    	<br />0.5mg was used as reliever medication as-needed<br />throughout the run in and treatment period. The primary<br />
                    	outcome was clinic pre-dose FEV<sub>1</sub> evaluated as <br /> change from randomisation to 12 weeks.
                    	</li>

                    </ul>
                    <ul class="bodyContentRight">
                    	<li>Over 12 weeks of treatment:<sup>1</sup></li>
                    	<li>Symbicort 400/12 bd + tiotropium significantly<br /> prolonged time to first exacerbation vs. tiotropium<br />+ placebo; 
                    		<em>p< 0.001</em></li>
                    	<li>Symbicort 400/12 bd + tiotropium significantly<br />improved post-dose FEV<sub>1</sub> by 11% (at both 5 and<br />
                    		60 minutes post-dose) vs. tiotropium + placebo;<br /><em>p< 0.001</em>
                    	</li>
                    	<li>Reference: 1. Welte T <em>et al. Am J Respir Crit Care Med.</em> 2009; 180:741-50.
                    </ul>
        </div>
    </section>

<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
	$( function(){

	});



</script>
</body>
</html>
